Thurston Springer Miller Herd & Titak’s AstraZeneca AZN Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$170K	Sell	896 -1	-0.1%	-$188	0.06%	272
2026 Q1	$177K	Sell	897 -3	-0.3%	-$578	0.07%	277
2025 Q4	$165K	Buy	+900	New	+$158K	0.06%	275
2025 Q3	–	Sell	-2,312	Closed	-$323K	–	600
2025 Q2	$323K	Buy	2,312 +11	+0.5%	+$1.54K	0.04%	301
2025 Q1	$338K	Buy	2,301 +265	+13%	+$38.3K	0.06%	237
2024 Q4	$267K	Buy	2,036 +243	+14%	+$34K	0.05%	241
2024 Q3	$279K	Buy	1,793 +850	+90%	+$137K	0.08%	211
2024 Q2	$147K	Sell	943 -3,396	-78%	-$511K	0.05%	350
2024 Q1	$588K	Buy	+4,339	New	+$575K	0.24%	32

Other funds holding AZN

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

CDDEC

Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

BTCPP

Border to Coast Pensions Partnership Leeds, United Kingdom $6.78B AUM 31.6% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's AZN Position: Q2 2026 in Review

Thurston Springer Miller Herd & Titak reduced its AstraZeneca (AZN) stake by 0.11% in Q2 2026, selling an estimated $188 and leaving 896 shares worth $170K. The position accounts for 0.06% of the portfolio, ranked #272.

Thurston Springer Miller Herd & Titak first reported a position in AZN in Q1 2024 and has held it in 9 quarters since. The position peaked at $588K in Q1 2024. 534 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Thurston Springer Miller Herd & Titak held 896 shares of AstraZeneca worth $170K as of Q2 2026.
Thurston Springer Miller Herd & Titak sold 1 AstraZeneca share in Q2 2026, an estimated $188.
AstraZeneca made up 0.06% of Thurston Springer Miller Herd & Titak's portfolio in Q2 2026, its #272 holding.
Thurston Springer Miller Herd & Titak first reported a position in AstraZeneca in Q1 2024 and has held it in 9 quarters since.
Thurston Springer Miller Herd & Titak's AstraZeneca position peaked at $588K in Q1 2024.
534 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2026, filed 8 Jul 2026.